Remus Pharmaceuticals (NSE:REMUS) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
44 GF Score
Price ₹979.05
! 4 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals 3-Year EBITDA Growth Rate?

Remus Pharmaceuticals NSE:REMUS +0.71% 44 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2023. GuruFocus rates NSE:REMUS with a GF Score™ of 44/100. The stock has 4 warning signs investors should review. Among 108 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 925925% on this metric.

Remus Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2023 was ₹2.46.

During the past 12 months, Remus Pharmaceuticals's average EBITDA Per Share Growth Rate was 25.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Remus Pharmaceuticals was 176.80% per year. The lowest was 119.70% per year. And the median was 148.25% per year.

Remus Pharmaceuticals  (NSE:REMUS) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Remus Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

NSE:REMUS vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison

For the Medical Distribution subindustry, Remus Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Remus Pharmaceuticals 3-Year EBITDA Growth Rate vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Remus Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.


NSE:REMUS
44GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Remus Pharmaceuticals (NSE:REMUS) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2023. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Remus Pharmaceuticals and its competitors. Over the past decade, Remus Pharmaceuticals' 3-Year EBITDA Growth Rate has ranged from 119.70 to 176.80. According to the industry distribution chart, Remus Pharmaceuticals ranks #999999 out of 108 companies in the Medical Distribution industry.
Is Remus Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Remus Pharmaceuticals' current 3-Year EBITDA Growth Rate is 0.00%. Over the past 10 years, this metric has ranged from a low of 119.70 to a high of 176.80. Based on the distribution chart, Remus Pharmaceuticals ranks #999999 out of 108 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #999999 out of 108 companies for 3-Year EBITDA Growth Rate. This places Remus Pharmaceuticals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 6.10. Historically, Remus Pharmaceuticals' own 3-Year EBITDA Growth Rate has ranged from 119.70 to 176.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 6.10, based on 108 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 6.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Remus Pharmaceuticals (NSE:REMUS) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Remus Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
44GF Score

Get the complete analysis for NSE:REMUS

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹979.05
Price